Health & Wellness

10/01/2026 · Greene County

Eli Lilly's EloraTZP Shows Greater Weight and A1C Reduction in Phase 2b Trial

Eli Lilly's experimental drug EloraTZP, a combination of eloralintide and tirzepatide, demonstrated superior weight loss and A1C reduction compared to tirzepatide 15 mg in a 48-week Phase 2b study. Participants taking EloraTZP lost significantly more weight and saw greater improvements in their blood sugar levels.

10/01/2026

Read Story

Health

UK Study Investigates Personalized Pain Management for Endometriosis

A new UK study will explore whether individualized pain management plans can improve quality of life for women with endometriosis. The research, backed by £2.3 million in funding, involves multiple institutions across the country.

10/01/2026